Bronchodilator Drugs - Belgium | Statista Market Forecast

The Bronchodilator Drugs market in Belgium is expected to witness significant growth in the coming years.
By 2024, the projected revenue for this market is estimated to reach US$142.40m.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 3.15% between 2024 and 2029, leading to a market volume of US$166.30m by 2029.
In terms of global comparison, United States is set to generate the highest revenue in the Bronchodilator Drugs market.
In 2024 alone, the projected revenue for the United States is estimated to reach a staggering US$17.34bn.
This indicates the significant market potential and demand for Bronchodilator Drugs market United States.
Belgium's bronchodilator drug market is experiencing a shift towards more personalized and targeted treatments.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are medications that relax the muscles in the airways and lungs, making it easier to breathe. In Belgium, the Bronchodilator Drugs market has been witnessing steady growth over the past few years.

Customer preferences: Belgian consumers have been increasingly turning towards bronchodilator drugs due to the rising prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Moreover, the aging population in Belgium has also been a contributing factor to the growth of the market as older adults are more susceptible to respiratory illnesses.

Trends in the market: One of the major trends in the Bronchodilator Drugs market in Belgium is the shift towards combination therapies. Combination therapies involve the use of two or more bronchodilator drugs in a single inhaler, providing better symptom control and reducing the need for multiple inhalers. Another trend is the increasing preference for long-acting bronchodilators over short-acting ones. Long-acting bronchodilators provide sustained relief and require less frequent dosing, making them more convenient for patients.

Local special circumstances: Belgium has a well-established healthcare system that provides universal coverage for its citizens. This has led to increased access to healthcare services, including respiratory care. Additionally, the Belgian government has been implementing various measures to promote smoking cessation and reduce exposure to air pollution, which are major risk factors for respiratory diseases.

Underlying macroeconomic factors: The Bronchodilator Drugs market in Belgium is also influenced by macroeconomic factors such as GDP growth, healthcare spending, and regulatory policies. The Belgian economy has been growing steadily over the past few years, which has led to increased healthcare spending. Moreover, the government has been implementing various regulatory policies to promote the use of generic drugs, which has led to increased competition and lower prices in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.